<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2021000300263</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2021000300003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectividad y seguridad de evolocumab en la práctica clínica]]></article-title>
<article-title xml:lang="en"><![CDATA[Effectiveness and safety of evolocumab in clinical practice]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Gundín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Illaro Uranga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llorente Serrano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Torrón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Gómez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valero Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Marqués de Valdecilla Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Santander ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Virgen de la Luz Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>31</volume>
<numero>3</numero>
<fpage>263</fpage>
<lpage>267</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2021000300263&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2021000300263&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2021000300263&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Evaluar efectividad y seguridad de evolocumab en la reducción de los datos analíticos referentes al colesterol.  Material y métodos:  Estudio observacional, descriptivo y retrospectivo de pacientes tratados con evolocumab durante 12 o más semanas (mayo 2017-mayo 2019). Variables recogidas: demográficas, relacionadas con tratamiento y aparición eventos cardiovasculares.  Efectividad:  datos analíticos, principalmente colesterol ligado a lipoproteínas de baja densidad (c-LDL) basal y en semana 12, 24 y 48. Seguridad: efectos adversos.  Resultados:  Se identificaron 79 pacientes, mayoría varones (54%) y edad media 62 años. El 23% de los pacientes presentaban hipercolesterolemia familiar heterocigótica y el 1% homocigótica. El 58% de los pacientes presentaban enfermedad cardiovascular y el 96% había sido tratado con estatinas. El 63% de los pacientes fueron tratados con evolocumab en combinación. Efectividad: el nivel medio de c-LDL basal, en semana 12, 24 y 48, fue de 151 mg/dL, 71 mg/dL, 74 mg/dL y 72 mg/dL, respectivamente. A la semana 12, el c-LDL se había reducido en un 53%, datos mantenidos constantes. Seguridad: el 59% de los pacientes presentaron reacciones adversas, un 1% tuvo que reducir posología y un 4% suspender tratamiento. Al cierre del estudio, el 92% de los pacientes continuaban tratamiento tras una mediana de 49 semanas. Durante el tratamiento, el 3% de los pacientes sufrieron algún evento cardiovascular.  Conclusiones:  Evolocumab reduce los niveles de c-LDL aproximadamente a la mitad en la semana 12, datos mantenidos en el tiempo y semejantes a los publicados. En seguridad, los resultados obtenidos son semejantes a los hallados previamente y en ficha técnica. Por tanto, evolocumab constituye una alternativa terapéutica para el tratamiento de la hipercolesterolemia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary  Introduction:  To evaluate the effectiveness and safety of evolocumab in the reduction of analytical data related to cholesterol.  Material and methods:  Observational, descriptive and retrospective study of patients treated with evolocumab for 12 or more weeks (May 2017-May 2019). Variables collected: demographic, related to treatment and appearance of cardiovascular events. Effectiveness: analytical data, mainly low density lipoprotein cholesterol (LDL-c) basal and at week 12, 24 and 48. Safety: adverse events.  Results:  79 patients were identified, mostly males (54%), mean age 62 years. A 23% of patients had heterozygous familial hypercholesterolemia and 1% homozygous. A 58% of patients had cardiovascular disease and a 96% had been treated with statins. A 63% os patients were treated with evolocumab in combination. Effectiveness: mean level of LDL-c basal, at week 12, 24 and 48, were 151 mg/dL, 71 mg/dL, 74 mg/dL and 72 mg/dL, respectively. At week 12, LDL-c had been reduced by 53%, data kept constant. Safety: 59% of patients presented adverse events, 1% had to reduce the posology and 4% had to stop treatment. At the end of the study, 92% of patients continued treatment after a median of 49 weeks. During the treatment, 3% of patients suffered a cardiovascular event.  Conclusions:  Evolocumab reduces LDL-c levels by approximately half in week 12, data maintained over time and similar to those published. In safety, the results obtained are similar to those previously found and in summary of product characteristics. Therefore, evolocumab is a therapeutic alternative for the treatment of hypercholesterolemia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Evolocumab]]></kwd>
<kwd lng="es"><![CDATA[efectividad]]></kwd>
<kwd lng="es"><![CDATA[seguridad]]></kwd>
<kwd lng="es"><![CDATA[efectos adversos]]></kwd>
<kwd lng="en"><![CDATA[Evolocumab]]></kwd>
<kwd lng="en"><![CDATA[effectiveness]]></kwd>
<kwd lng="en"><![CDATA[safety]]></kwd>
<kwd lng="en"><![CDATA[adverse events]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Informe de Posicionamiento Terapéutico de evolocumab (Repatha®) en hipercolesterolemia]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Townsend]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatnagar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wickramasinghe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rayner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease in Europe: epidemiological update 2016]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>42</numero>
<issue>42</issue>
<page-range>3232-45</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Sanchidrián]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Labrador Gómez]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar Aguilar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Davin Carrero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gallego Domínguez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Martino Arroyo]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolocumab para el tratamiento de la hipercolesterolemia familiar heterocigota en enfermedad renal crónica avanzada y diálisis]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2019</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>218-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piepoli]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Hoes]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Agewall]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albus]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brotons]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2016</year>
<volume>69</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>939.e1-939.e87</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Botet]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pintó]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una visión actualizada del tratamiento hipolipemiante de alta intensidad en los pacientes de alto riesgo cardiovascular]]></article-title>
<source><![CDATA[Clin Investig Arterioscler]]></source>
<year>2016</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-30</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pintó]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[García Gómez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevos tratamientos para la hipercolesterolemia]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2016</year>
<volume>146</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corral]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber]]></article-title>
<source><![CDATA[Hipertens Riesgo Vasc]]></source>
<year>2017</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>176-83</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Denenberg]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Golomb]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statin-Associated Muscle-Related Adverse Effects: A Case Series of 354 Patients]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2010</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>541-53</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<collab>CIMA: Centro de Información Online de Medicamentos de la AEMP</collab>
<source><![CDATA[Ficha técnica evolocumab]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Raal]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of evolocumab in reducing lipids and cardiovascular events]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1500-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koren]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Raal]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Langslet]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Longer-term Administration of Evolocumab (AMG 145) in Patients with Hypercholesterolemia: 52-week Results from the Open-label Study of Long-term Evaluation Against C-LDL (OSLER) Randomized Trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2014</year>
<volume>129</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>234-43</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarese]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Kolodziejczak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kereiakes]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tantry]]></surname>
<given-names><![CDATA[US]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Connor]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gurbel]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2016</year>
<volume>164</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>600-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koren]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lundqvist]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Monsalvo]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2531-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nedergaard]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fialkow]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Neutel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramstad]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1870-82</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raal]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Civeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>385</volume>
<numero>9965</numero>
<issue>9965</issue>
<page-range>331-40</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stroes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Colquhoun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Civeira]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenson]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[GF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2541-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaudhary]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sumner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PCSK9 inhibitors: A new era in the management of atherosclerotic cardiovascular disease]]></article-title>
<source><![CDATA[World J Cardiol]]></source>
<year>2017</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-91</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliano]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Keech]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Honarpour]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1713-22</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blom]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hala]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bolognese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lillestol]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 52-week placebo-controlled trial of evolocumab in hyperlipidemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1809-19</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cidoncha Muñoz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Nieto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Herraiz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Abanades]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Puiz García]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morell Baladrón]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y seguridad de evolocumab en la reducción de los niveles de colesterol unido a lipoproteínas de baja densidad]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Libro de comunicaciones SEFH 2017]]></source>
<year></year>
<page-range>531</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villamayor Blanco]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fortes González]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Domínguez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez Blanco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[De Miguel Bouzas]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero Poch]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia y seguridad de evolocumab en el tratamiento de la hipercolesterolemia]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Libro de comunicaciones SEFH 2018]]></source>
<year></year>
<page-range>402</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González González]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreras López]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega Valin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Flores Vergara]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[García Del Egido]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Nuñez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Álvarez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra González]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modificación del perfil lipídico en pacientes tratados con evolocumab]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Libro de comunicaciones SEFH 2018]]></source>
<year></year>
<page-range>402</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talens Bolos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laborda Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Herraiz Robles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bonete Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marcos Ribes]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Campillo López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aznar Saliente]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad y seguridad de evolocumab]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Libro de comunicaciones SEFH 2017]]></source>
<year></year>
<page-range>590</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
